bioRxiv/medRxiv TRiP Review Activity

78 Reviews — EMBO Press — Cancer Biology

Most recent first Previous |  Page 8: Articles 71-78

Whole chromosome loss in tetraploid cells confers tumorigenic potential in a mouse allograft model
Thomas, R., Marks, D. H., Chin, Y., Benezra, R.
10.1101/172668 — Posted: 2017-08-04 — Discussion: 2019-09-22  EMBO Press
Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Sahu, A., Sang Lee, J., Zhang, G., Wang, Z., Tian, T., Moll, T., Kasumova, G., Miao, B., Wei, Z., Nair, N. U., Ponomarova, O., Friedman, A., Amzallag, A., Greninger, P., Egan, R., Damon, L., Frederick, D., Jerby-Arnon, L., Wagner, A., Cheng, K., Robinson, W., Park, S. G., Gardner, K., Hannenhalli, S., Gutkind, S., Boland, G., Flaherty, K., Benes, C., Herlyn, M., Bartolome, R., Ruppin, E.
10.1101/284240 — Posted: 2018-03-18 — Discussion: 2019-09-22  EMBO Press
Tumor-Intrinsic Response to IFNgamma Shapes the Tumor Microenvironment and Anti-PD-1 Response in NSCLC
Bullock, B. L., Kimball, A. K., Poczobutt, J. M., Li, H. Y., Kwak, J. W., Neuwelt, A. J., Johnson, A. M., Kleczko, E., Kaspar, R., Hopp, K., Schenk, E., Weiser-Evans, M. C., Clambey, E. T., Nemenoff, R. A.
10.1101/531236 — Posted: 2019-01-27 — Discussion: 2019-09-22  EMBO Press
Resolving Drug Effects In Patient-Derived Cancer Cells Links Organoid Responses To Genome Alterations
Neugebauer, J., Zickgraf, F. M., Park, J., Wagner, S., Jiang, X., Jechow, K., Kleinheinz, K., Toprak, U. H., Schneider, M. A., Meister, M., Spaich, S., Suetterlin, M., Schlesner, M., Trumpp, A., Sprick, M., Eils, R., Conrad, C.
10.1101/124446 — Posted: 2017-04-06 — Discussion: 2019-09-22  EMBO Press
Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells
Murmann, A. E., Gao, Q. Q., Putzbach, W., Patel, M., Bartom, E. T., Law, C., Bridgeman, B., Chen, S., McMahon, K. M., Thaxton, C. S., Peter, M. E.
10.1101/247429 — Posted: 2018-01-12 — Discussion: 2019-09-22  EMBO Press
Functional systemic CD4 immunity is a differential factor for clinical responses to PD-L1/PD-1 blockade therapy in lung cancer
Zuazo, M., Arasanz, H., Fernandez-Hinojal, G., Garcia-Granda, M. J., Gato, M., Bocanegra, A., Hernandez, B., Martinez, M., Teijeira, L., Morilla, I., Lecumberri, M. J., Fernandez de Lascoiti, A., Vera, R., Kochan, G., Escors, D.
10.1101/508739 — Posted: 2019-01-09 — Discussion: 2019-09-22  EMBO Press
Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
Miettinen, T. P., Peltier, J., Hartlova, A., Gierlinski, M., Jansen, V. M., Trost, M., Bjorklund, M.
10.1101/202770 — Posted: 2017-10-13 — Discussion: 2019-09-22  EMBO Press
FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice.
Orthwein, A., Findlay, S., Heath, J., Luo, V., Malina, A., Li, Z., Samiei, A., Cheyou, E. S., Karam, M., Bagci, H., Rahat, D., Grapton, D., Lavoie, E. G., Dove, C., Khaled, H., Mann, K., Klein, K. O., Tabach, Y., Cote, J.-F., Marechal, A., Morin, T., Djerir, B., Park, M. M., Kuasne, H.
10.1101/365460 — Posted: 2018-07-11 — Discussion: 2019-09-22  EMBO Press

Evaluation Sources